Disease overview The myelodysplastic syndromes (MDS) are a very heterogeneous group
of myeloid disorders characterized by peripheral blood cytopenias and increased risk of …

Myelodysplastic syndromes (MDS) represent a heterogeneous group of myeloid neoplasms
that are characterized by ineffective hematopoiesis, variable cytopenias, and a risk of …

Background Myelodysplastic syndromes are clinically heterogeneous disorders
characterized by clonal hematopoiesis, impaired differentiation, peripheral-blood …

Disease overview The myelodysplastic syndromes (MDS) are a very heterogeneous group
of myeloid disorders characterized by peripheral blood cytopenias and increased risk of …

This review gives an account of the clinical and hematologic features of the myelodysplastic
syndromes. It supplies the latest classification of these disorders, discusses the cytogenetic …

Purpose A subset of patients with myelodysplastic syndromes (MDS) who are predicted to
have lower-risk disease as defined by the International Prognostic Scoring System (IPSS) …

Myelodysplastic syndromes are clonal marrow stem-cell disorders, characterised by
ineffective haemopoiesis leading to blood cytopenias, and by progression to acute myeloid …

Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal stem cell disorders
with an inherent tendency for leukemic transformation. Diagnosis is currently based on the …

Hypomethylating agents (HMAs) improve survival in patients with higher-risk
myelodysplastic syndromes (MDS) but are less well-studied in lower-risk disease. We …

Once thought to be rare disorders, the myelodysplastic syndromes (MDS) are now
recognized as among the most common hematological neoplasms, probably affecting> 30 …